See more : Fantasma Games AB (publ) (FAGA.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Sigilon Therapeutics, Inc. (SGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sigilon Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SpareBank 1 Sørøst-Norge (SOON.OL) Income Statement Analysis – Financial Results
- Bogota Financial Corp. (BSBK) Income Statement Analysis – Financial Results
- Bank of Cyprus Holdings Public Limited Company (BKCYF) Income Statement Analysis – Financial Results
- Zhejiang MustangBattery Co.,Ltd (605378.SS) Income Statement Analysis – Financial Results
- Sino Green Land Corporation (SGLA) Income Statement Analysis – Financial Results
Sigilon Therapeutics, Inc. (SGTX)
About Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 37.63M | 65.07M | 53.49M | 48.11M | 21.04M |
| General & Administrative | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Other Expenses | 1.45M | 55.00K | -89.00K | -6.00K | -81.00K |
| Operating Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Cost & Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Interest Income | 946.00K | 258.00K | 312.00K | 1.06M | 698.00K |
| Interest Expense | 2.29M | 1.99M | 1.20M | 650.00K | 289.00K |
| Depreciation & Amortization | 2.40M | 313.00K | 223.00K | 1.73M | 374.00K |
| EBITDA | -41.27M | -75.32M | -52.42M | -42.40M | -22.08M |
| EBITDA Ratio | -318.84% | -784.70% | -391.95% | -299.51% | -476.26% |
| Operating Income | -43.67M | -75.64M | -52.64M | -44.12M | -23.08M |
| Operating Income Ratio | -337.35% | -787.96% | -393.61% | -311.71% | -497.63% |
| Total Other Income/Expenses | 105.00K | -1.68M | -1.97M | 198.00K | 310.00K |
| Income Before Tax | -43.56M | -77.31M | -54.61M | -43.93M | -22.77M |
| Income Before Tax Ratio | -336.53% | -805.41% | -408.31% | -310.31% | -490.94% |
| Income Tax Expense | -105.00K | 925.00K | 259.00K | 644.00K | 599.00K |
| Net Income | -43.46M | -78.24M | -54.87M | -44.57M | -22.77M |
| Net Income Ratio | -335.72% | -815.04% | -410.25% | -314.86% | -490.94% |
| EPS | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| Weighted Avg Shares Out | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
| Weighted Avg Shares Out (Dil) | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Source: https://incomestatements.info
Category: Stock Reports